Arena Pharmaceuticals and Eisai Announce FDA Approval of Belviq (lorcaserin HCl) for Chronic Weight Management in Adults who are Overweight with a Comorbidity or Obese
14:06 EDT 27 Jun 2012 | Drugs.com
SAN DIEGO and WOODCLIFF LAKE, N.J., June 27, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Belviq (pronounced BEL-VEEK) as an adjunct to...
More From BioPortfolio on "Arena Pharmaceuticals and Eisai Announce FDA Approval of Belviq (lorcaserin HCl) for Chronic Weight Management in Adults who are Overweight with a Comorbidity or Obese"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
